+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
S

Actively Recruiting

Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.

Age: 18Years +All GendersPhase Not Applicable
98 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of whole-body hypothermia for newborn babies with mild hypoxic ischaemic encephalopathy. This phase III randomised controlled trial aims to determine whether cooling the whole body to 33.5.5C within six hours after birth and continuing for 72 hours improves cognitive development at around two years of age compared with maintaining normal body temperature. The study also seeks to assess the economic value of cooling therapy for mild encephalopathy within the healthcare system. Babies born at or after 36 weeks with signs of birth asphyxia or acidosis will be randomly assigned to receive either whole-body hypothermia or targeted normothermia. Cooling will be applied using a servo-controlled machine in neonatal intensive care units, maintaining a rectal temperature of about 33.5C for 72 hours. The control group will have their body temperature kept at normal levels 37C for the first 80 hours, with any fever carefully treated. Babies born at non-cooling centers will be transferred to specialized units for treatment. During the study, participants will undergo brain monitoring, MRI scans before discharge, and follow-up developmental assessments at 24 months using the Bayley Scales of Infant and Toddler Development IV. Additional evaluations will include neurological exams, motor function assessments, vision and hearing tests, and parent-completed questionnaires. Researchers will collect detailed clinical data from birth through hospital stay, aiming to compare cognitive outcomes and safety measures between the two groups over the study period.

Age: 1Hour - 6HoursAll GendersPhase 3
39 locations
I

Actively Recruiting

This research investigates whether personalized medical treatment guided by a special diagnostic procedure during invasive coronary angiography can improve symptoms, wellbeing, cardiovascular risk, and clinical outcomes in patients with angina but no significant blockage in their coronary arteries. It focuses on patients with ischaemic heart disease, particularly those with angina without obstructive coronary artery disease INOCA, a condition affecting the small vessels of the heart. The trial builds on earlier pilot studies that suggested this approach could improve quality of life and symptom control by tailoring diagnosis and treatment more precisely. Participants undergo functional coronary angiography with a guidewire-based interventional diagnostic procedure IDP that measures coronary vascular function to classify patients into specific diagnosis groups, such as microvascular or vasospastic angina. Eligible patients are randomized into two groups one where IDP results are disclosed to clinicians to guide treatment, and another where IDP is performed but results are hidden, with care based on standard angiography and clinical information. Both groups receive medical therapy and lifestyle advice based on their diagnosis. The study also includes a registry for patients with obstructive disease who are not randomized. During the study, participants complete symptom questionnaires like the Seattle Angina Questionnaire to assess their angina symptoms and quality of life over at least 12 months. Researchers monitor health status, clinical outcomes, safety, and health economics, with ongoing follow-up planned for up to 10 years. Both patients and their usual care clinicians are blinded to the group allocation, but informed about the diagnosis to guide treatment. The trial aims to enroll 1500 participants across multiple centers in Europe, assessing the feasibility and impact of this stratified medicine approach.

Age: 18Years +All GendersPhase Not Applicable
39 locations
S

Actively Recruiting

Researchers are exploring how the gut microbiome affects patients with gallstone disease. This observational study aims to find out if changes in the gut microbiome are linked to complications like pancreatitis and acute cholecystitis, and how the microbiome changes after gallbladder removal surgery cholecystectomy. The study focuses on adult patients diagnosed with gallstone disease and tracks their outcomes over time. Participants will provide stool samples at several fixed times at diagnosis, before and after any gallbladder surgery if applicable, and then at 6 months and 3 years later. Samples are collected either during hospital admission or at home and mailed to the research team for analysis. They will also complete a 3-day food diary. Clinical data from patient records, including medical history, imaging, blood tests, and follow-up visits, will be collected too. Throughout the study, patients are monitored for complications pre- and post-surgery. The primary measure is the bacterial DNA profile from stool samples, tracked up to 3 years after surgery. This research will help understand how microbiome differences relate to patient outcomes and may guide future interventions to reduce complications. Participation involves stool sample collection and clinical data review over several years.

Age: 18Years +All Genders
1 location
U

Actively Recruiting

Researchers are evaluating the Heartfelt device, a new passive monitoring system that detects early signs of fluid build-up in patients with heart failure by measuring changes in foot and lower leg volume using 3D images. The study aims to see if adding this device to standard NHS care improves quality of life and reduces heart failure-related events compared to standard care alone. The trial involves 300 participants from multiple NHS hospitals and GP practices across the UK and uses a randomized crossover design. Participants will be randomly assigned to receive either standard NHS care, which includes regular weight checks and symptom monitoring, or standard care plus the Heartfelt device installed at home. The device captures daily images of the feet to track swelling without extra effort from the user. Alerts triggered by important changes are sent to the clinical team for prompt action. Both groups receive a patient booklet from the British Heart Foundation to support self-monitoring and understanding of heart failure. During the study, participants quality of life will be assessed using questionnaires at baseline and at 3, 6, 9, and 12 months. The study will also monitor hospitalizations, deaths, medication adherence, and the availability of daily device data. Researchers will evaluate how the clinical teams respond to alerts, the ease of device use, and its cost-effectiveness. The total participation period covers 12 months of monitoring and data collection.

Age: 18Years +All GendersPhase Not Applicable
18 locations
E

Actively Recruiting

Spontaneous coronary artery dissection SCAD is a recognized cause of non-atherosclerotic acute coronary syndromes, mainly affecting young women without typical risk factors. Researchers are building the first pan-European SCAD registry to improve understanding of this conditions diagnosis and management, inform guidelines, educate clinicians, and promote research. This international, multicenter, observational study includes both retrospective and prospective patient data. The study collects data without any treatment interventions, enrolling at least 500 new patients and 500 historical cases from about 30 countries and 120 sites. Patient information is gathered from their first SCAD event, at enrollment, and then yearly for up to five years or until study completion. There are no study drugs or procedures involved as it is purely observational. Participants will provide data at multiple time points including baseline and yearly follow-ups for up to five years. Researchers will review patient status, vital signs, recurrent SCAD events, imaging results, medications, menstrual and obstetric history, and discharge details. Additional information on procedures, other coronary events, symptoms, pregnancy and hormonal therapy, exercise habits, mental health, and employment after SCAD will also be collected. This allows a comprehensive understanding of SCAD over time.

Age: 18Years +All Genders
73 locations
E

Actively Recruiting

This research aims to evaluate two types of ostomy seals or rings in patients who have recently undergone ostomy surgery. It focuses on preventing and managing complications related to the skin around the stoma, known as peristomal skin complications PSCs. The study is sponsored by Hollister Incorporated and involves post-operative patients with colostomy, ileostomy, or urostomy, assessing how these devices perform in real-world use. Participants will be randomly assigned to use either an absorptive ostomy seal or an ostomy ring containing Aloe. These devices are applied at the first pouch change following surgery or up to four days after the operation. The study treatment period lasts for nine weeks, during which patients use the assigned seal or ring as part of their ostomy care. The trial compares the two devices to monitor skin complications and other related outcomes. During the study, participants will be followed from enrollment through the nine-week treatment phase with regular assessments. Researchers will track skin complications using the Ostomy Complication Severity Index OCSI, including measures of leakage, moisture, skin conditions, and patient and clinician satisfaction. The study also collects data on usage patterns, healthcare visits related to the ostomy, and costs associated with the seals or rings. The overall goal is to understand the devices impact on skin health and patient experience after ostomy surgery.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
6 locations
S

Actively Recruiting

This research aims to collect and analyze information about babies born at 22 weeks of pregnancy in the UK to better understand their clinical care and outcomes. Since survival-focused care for these extremely premature babies has only been offered since 2019, there is limited data on how they respond to treatment and what challenges they face. The study gathers data from multiple neonatal intensive care units NICUs across the UK to improve knowledge for future care and support families. Data collection involves medical staff entering selected, anonymized information from babies medical records into a secure database. The study observes babies who are attended by neonatal teams at birth or admitted to NICUs within the first 72 hours of life. No changes are made to the babies care during the study, and a one-time survey of NICUs will assess unit approaches and equipment used for 22-week babies. Participants data, including clinical care details and short-term outcomes such as survival to discharge, are analyzed. Researchers will report on interventions across various care areas and outcomes like brain injury or infections. Parents receive information about data use, and individual babies cannot be identified in results. The study runs from admission until death or discharge from neonatal care, aiming to inform future research and improve care practices.

All AgesAll Genders
50 locations
I

Actively Recruiting

This research aims to compare two standard care approaches in very premature infants born before 30 weeks to see if withholding enteral feeds around the time of blood transfusion reduces the risk of Necrotizing Enterocolitis NEC, a serious intestinal disease. NEC can severely damage the bowel and has a high risk of death or long-term health problems. The study involves infants from neonatal intensive care units in Canada and the UK and evaluates if withholding or continuing feeds during transfusion affects outcomes. The study randomly assigns infants to one of two groups one where all enteral feeds are stopped for 4 hours before, during, and after packed red cell transfusion and another where feeding continues as usual throughout the transfusion period. Infants will remain on their assigned feeding strategy until reaching 34 weeks and 6 days gestational age. During feed withholding, hydration and blood sugar are maintained by parenteral nutrition or intravenous glucose according to local practice. Participants will be monitored from randomization until 40 weeks postmenstrual age for the development and severity of NEC, death, infections, nutritional support duration, growth, and other health outcomes. Researchers will track feeding practices, transfusions, and clinical events, with long-term follow-up until discharge from the hospital. The study intends to identify which feeding approach during transfusion might better prevent NEC in these vulnerable infants.

Age: 0 - 30WeeksAll GendersPhase Not Applicable
40 locations